National Cancer Institute; Amended Notice of Meeting, 48355 [2010-19681]
Download as PDF
<![CDATA[
48355
Federal Register / Vol. 75, No. 153 / Tuesday, August 10, 2010 / Notices
TABLE 1.—LIST OF REGULATIONS—Continued
21 CFR Section
FCC Edition and/or Supplement
Currently Referenced
Name of Additive
Current FCC Reference
173.165(d)
3d Ed.
Candida lipolytica
Citric acid produced must conform to FCC
specifications (under ‘‘Citric acid’’).
173.228(a)
4th Ed.
Ethyl acetate
Meets FCC specifications.
173.280(c)
3d Ed.
Solvent extraction
process for citric acid
Meets FCC specifications.
173.310(c)
4th Ed.
Boiler water additives;
Sodium
carboxymethylcellulose
Contains not less than 95% sodium
carboxymethylcellulose on a dry-weight basis,
with maximum substitution of 0.9
carboxymethylcellulose groups per
anhydroglucose unit, and with a minimum
viscosity of 15 centipoises for 2% by weight
aqueous determined by the method cited in FCC.
173.310(c)
4th Ed.
Boiler water additives;
Sorbitol anhydride esters
Meets FCC specifications.
173.368(c)
4th Ed.
Ozone
Meets FCC specifications.
178.1005(c)
3d Ed.
Hydrogen peroxide
solution
Meets FCC specifications.
180.25(b)
3d Ed.
Mannitol
Meets FCC specifications.
180.30(a)
3d Ed.
Brominated vegetable oil
Meets FCC specifications.
180.37(b)
3d Ed.
Saccharin, ammonium
saccharin, calcium
saccharin, and sodium
saccharin
Meets FCC specifications.
The agency has determined under 21
CFR 25.30(i) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
Dated: August 4, 2010.
Catherine L. Copp,
Acting Director, Office of Food Additive
Safety, Center for Food Safety and Applied
Nutrition.
Federal Register on July 22, 2010, 75
FR42758.
This amendment has been processed
to change the start and end times of the
NCAB meeting. The meeting will now
start at 4 p.m. and end at 5:45 p.m. on
September 7, 2010. On September 8,
2010, the closed session will be held
from 8:30 a.m. to 10 a.m. The open
session will start at 10:15 a.m. and end
at 5 p.m.
[FR Doc. 2010–19722 Filed 8–9–10; 8:45 am]
Dated: August 4, 2010.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4160–01–S
[FR Doc. 2010–19681 Filed 8–9–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
sroberts on DSKB9S0YB1PROD with NOTICES
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, September 7, 2010,
8:30 a.m. to September 8, 2010, 12 p.m.,
National Institutes of Health, Building
31, 31 Center Drive, Bethesda, MD
20892, which was published in the
VerDate Mar<15>2010
16:26 Aug 09, 2010
Jkt 220001
Prospective Grant of Exclusive
License: Griffithsin, GlycosylationResistant Griffithsin, and Related
Conjugates as Biotherapeutics for the
Treatment of HIV and HCV Infections
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the inventions
embodied in:
1. U.S. Provisional Patent Application
Serial No. 60/576,056, filed on June 1,
2004, entitled ‘‘Griffithsin,
Glycosylation-Resistant Griffithsin, and
Related Conjugates, Compositions,
Nucleic Acids, Vectors, Host Cells,
Methods of Production And Methods of
Use’’, converted to PCT/US2005/18778,
filed May 27, 2005, and entered national
stage in U.S. (patent application serial
number 11/569,813), Canada (patent
application serial number 2,567,728),
Australia (patent application serial
number 2005250429), Europe (patent
application serial number 05804849.7),
Japan (patent application serial number
2007–515398), Israel (patent application
serial number 179236), New Zealand
(patent number 2006/09573), and South
Africa (patent application serial number
2006/09573) (HHS reference E–106–
2003/0) from Dr. Barry O’Keefe et al.
(NCI).
2. U.S. Provisional Patent Application
Serial No. 60/741.403, filed on
SUMMARY:
E:\FR\FM\10AUN1.SGM
10AUN1
]]>Agencies
[Federal Register Volume 75, Number 153 (Tuesday, August 10, 2010)]
[Notices]
[Page 48355]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-19681]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Advisory Board, September 7, 2010, 8:30 a.m. to September 8,
2010, 12 p.m., National Institutes of Health, Building 31, 31 Center
Drive, Bethesda, MD 20892, which was published in the Federal Register
on July 22, 2010, 75 FR42758.
This amendment has been processed to change the start and end times
of the NCAB meeting. The meeting will now start at 4 p.m. and end at
5:45 p.m. on September 7, 2010. On September 8, 2010, the closed
session will be held from 8:30 a.m. to 10 a.m. The open session will
start at 10:15 a.m. and end at 5 p.m.
Dated: August 4, 2010.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-19681 Filed 8-9-10; 8:45 am]
BILLING CODE 4140-01-P
